MedTrace Logo

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

NCT02954991 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2024-04-22

Study results available
· View outcomes & findings →

Summary

The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Glesatinib

Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor

DRUG

Sitravatinib

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

DRUG

Mocetinostat

Mocetinostat is an HDAC inhibitor.

DRUG

Nivolumab

nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-07
Primary Completion
2021-11-04
Completion
2021-11-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02954991 on ClinicalTrials.gov